Enliven Therapeutics (NASDAQ:ELVN) Hits New 52-Week High on Analyst Upgrade

Enliven Therapeutics, Inc. (NASDAQ:ELVN) hit a new 52-week high during trading on Thursday after Mizuho raised their price target on the stock from $41.00 to $45.00. Mizuho currently has an outperform rating on the stock. Enliven Therapeutics traded as high as $36.72 and last traded at $35.53, with a volume of 6419955 shares trading hands. The stock had previously closed at $31.15.

Other equities research analysts have also issued reports about the stock. Wall Street Zen lowered shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Enliven Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $41.80.

Insiders Place Their Bets

In other news, COO Anish Patel sold 48,300 shares of the business’s stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $27.99, for a total transaction of $1,351,917.00. Following the transaction, the chief operating officer directly owned 215,011 shares of the company’s stock, valued at approximately $6,018,157.89. The trade was a 18.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Benjamin Hohl sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $29.58, for a total value of $295,800.00. Following the transaction, the chief financial officer owned 51,000 shares of the company’s stock, valued at approximately $1,508,580. This represents a 16.39% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 232,180 shares of company stock valued at $6,217,033 in the last 90 days. 25.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Enliven Therapeutics

A number of large investors have recently modified their holdings of ELVN. Vestal Point Capital LP increased its position in shares of Enliven Therapeutics by 230.2% during the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock valued at $58,982,000 after buying an additional 2,670,000 shares during the period. TCG Crossover Management LLC purchased a new stake in Enliven Therapeutics in the second quarter worth about $9,990,000. Duquesne Family Office LLC lifted its holdings in Enliven Therapeutics by 104.6% in the third quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock worth $19,393,000 after buying an additional 484,405 shares during the period. Spruce Street Capital LP bought a new stake in Enliven Therapeutics during the 4th quarter valued at approximately $6,870,000. Finally, Polar Capital Holdings Plc grew its holdings in shares of Enliven Therapeutics by 13.5% during the 4th quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company’s stock worth $54,111,000 after acquiring an additional 418,673 shares during the period. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Trading Up 14.1%

The stock has a market cap of $2.12 billion, a PE ratio of -19.10 and a beta of 0.33. The business has a fifty day simple moving average of $28.04 and a two-hundred day simple moving average of $22.72.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Tuesday, March 3rd. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06). On average, research analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.